Healthcare >> Analyst Interviews >> August 30, 2012

Hepatitis C Therapies Propel Growth in Biotech

Roden, Matthew
Matthew Roden is an Executive Director and Senior Analyst at UBS, leading coverage of large- and smid-cap biotechnology stocks. He joined UBS in 2010 and was named as a 2011 Institutional Investor All-America Research Team Rising Star in biotechnology. Previously, Dr. Roden was a lead small- to mid-cap biotech Analyst at Bank of America Merrill Lynch as well as J.P. Morgan, where he also served as the Vice President on the Institutional Investor, number-two-ranked biotech franchise. He holds a Ph.D. in microbiology and immunology from the Albert Einstein College of Medicine and was awarded a fellowship at the National Cancer Institute, where he studied cancer vaccines. Dr. Roden also holds an M.S. from Georgetown University and a B.S. from George Mason University. Profile
TWST: Would you begin with a brief introduction to your coverage area, including some of the specific names you follow?

Mr. Roden: I cover biotech companies of all cap ranges.